conditions

Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy, defined by fever occurring in the context of neutropenia. Prompt recognition and treatment are essential to reduce morbidity and mortality. This algorithm focuses on "high-risk" FN as defined in the ‘Early versus Late Stopping of Antibiotics in high-risk FN’ (ELSA-FN)  randomised control trial as expected absolute neutrophil count (ANC) <500 cells/mm3 for ≥7 days.